Neuronetics Investor Relations Material
Latest events
Q1 2025
Neuronetics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neuronetics Inc
Access all reports
Neuronetics Inc develops and markets non-invasive neurostimulation therapies for mental health disorders. The company’s primary product is a transcranial magnetic stimulation system used in the treatment of major depressive disorder and other psychiatric conditions. It serves healthcare providers in the United States. The company is headquartered in Malvern, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for Neuronetics Inc
Q1 2025
Neuronetics Inc
Q2 2024
Neuronetics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
STIM
Country
🇺🇸 United States